Overview of Codeinefosfaat Teva

Property	Description
Active ingredient	Codeine phosphate
Form	Tablet, Oral solution
Pharmacological class	Opioid analgesic, Antitussive
Common use	Symptomatic relief of pain and cough
Origin	Natural opioid derivative (opiate)

The Definitional Identity: Codeine's Class and Origin

Codeinefosfaat Teva is a medicinal product whose identity is rooted in its primary active component, codeine phosphate, which classifies it as a weak centrally acting analgesic and an antitussive agent. It belongs to the broader pharmacological category of opioid analgesics. The core active ingredient, codeine, is derived from naturally occurring compounds in the opium poppy (Papaver somniferum), establishing it as an opiate. This pharmacological profile establishes its role in pain and cough management.

Centrally acting agents such as codeine function by modulating pain signals, which is the primary therapeutic focus for Codeinefosfaat Teva.

Composition and Pharmaceutical Presentation

The active component in this medicine is codeine phosphate, specifically formulated as the hemihydrate for stability. Codeinefosfaat Teva is a single active ingredient product, typically administered via the oral route, available in the traditional dosage forms of a tablet or an oral solution. A recognized feature of this medicine is that codeine functions as a prodrug; its primary analgesic effect is contingent upon its metabolic conversion to the more potent compound, morphine. The final presentation of Codeinefosfaat Teva ensures a consistent means of delivery for patients seeking relief from cough or pain symptoms.

General Therapeutic Role

The general purpose of Codeinefosfaat Teva is to provide comprehensive symptomatic relief, often used in scenarios requiring mitigation of mild to moderate discomfort alongside the control of a persistent, non-productive cough. It delivers its analgesic function by modifying how the central nervous system processes pain signals. Its antitussive role is achieved by exerting a direct suppressive effect on the central nervous system's cough center, defining its specific utility as a dual-purpose agent for symptomatic relief.

Regulatory References

NIH: Codeine Prodrug Mechanism (NCBI)

Therapeutic Uses of Codeinefosfaat Teva

What Codeinefosfaat Teva Treats: Main Uses and Benefits

The primary role of Codeinefosfaat Teva is to provide supportive, symptomatic relief across specific domains involving increased discomfort or tension. Specifically, the medication is commonly used to help with mild to moderate pain, a persistent cough, and diarrhea.

This medication is applied across domains where additional symptomatic support is needed to address symptoms related to physical discomfort in the mild to moderate range. This use is often relevant in clinical settings, such as post-operative recovery, or for managing persistent, recurrent symptoms in contexts like palliative care. By easing the overall symptom load during these periods, the support provided contributes to improved day-to-day comfort.

“The medication is considered relevant for easing symptoms linked to inflammatory or irritative states and provides supportive relief when symptoms become temporarily overwhelming.”

The application of this medication is relevant for managing symptoms related to the irritative cough—specifically when the cough is non-productive and interferes with daily functioning or rest. The medication is also applied in managing intestinal symptoms, where it is relevant for managing symptoms related to organ-specific functional stress, assisting with maintaining functional stability in cases of persistent diarrhea.

Quick Fact: Relief for Key Symptoms
Codeine is commonly used to help manage symptoms when symptoms related to physical discomfort are particularly noticeable, when a dry cough is exhausting, or when persistent diarrhea requires supportive control.

Regulatory References

National Cancer Institute Dictionary

Eligibility and Restrictions for Use

Codeinefosfaat Teva’s eligibility for use is defined by strict regulatory criteria focusing on age, metabolism, and pre-existing health conditions.

The medicine is contraindicated and must not be used in several populations. This includes all children younger than 12 years of age, and adolescents younger than 18 years following tonsillectomy or adenoidectomy. Use is also strictly prohibited for patients known to be CYP2D6 ultra-rapid metabolisers of codeine, and for women who are breastfeeding due to the risk of serious infant harm. Patients with pre-existing conditions such as severe respiratory depression, severe bronchial asthma, severe hepatic dysfunction, or paralytic ileus are also ineligible for use.

For adolescents aged 12 to 18, use is not recommended if they have compromised respiratory function, such as severe lung disease or obstructive sleep apnea. Older adults and patients with renal or hepatic impairment are permitted to use the medicine but require restricted use and dosage reduction. For pregnant patients, prolonged use near term carries a risk of Neonatal Opioid Withdrawal Syndrome (NOWS) in the newborn. Eligibility is generally restricted to adults and adolescents (12+) for whom non-opioid treatments have been insufficient.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Codeinefosfaat Teva defines restrictions based on both drug metabolism and combined central nervous system effects, as documented by national health authorities.

Formal Restrictions and Contraindications

Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is formally prohibited, requiring a mandatory 14-day period without an MAOI before codeine can be used. Use is also contraindicated in individuals known to be CYP2D6 Ultra-Rapid Metabolizers, as this metabolic variation may lead to the generation of dangerously high levels of the active metabolite, morphine.

Pharmacodynamic (Additive) Effects

The co-administration of codeine with other Central Nervous System (CNS) Depressants, including alcohol, carries the documented risk of an additive pharmacodynamic effect resulting in profound sedation and respiratory depression. A separate risk of serotonin syndrome is documented with concomitant use of Serotonergic Drugs. Furthermore, co-administration with mixed agonist/antagonist opioids may reduce the expected analgesic effect.

Pharmacokinetic (Metabolic) Alterations

Drugs that function as CYP2D6 Inhibitors are documented to significantly increase codeine plasma concentrations while decreasing the levels of the active metabolite, morphine, which may lead to reduced analgesic efficacy. Interactions with CYP3A4 Inhibitors and Inducers are also noted to alter the systemic exposure of both codeine and its metabolites, potentially impacting efficacy or contributing to withdrawal symptoms. The profile also notes that codeine can antagonize the effect of prokinetic agents like metoclopramide.

Mechanism of Action

How Codeinefosfaat Teva Works: The Mechanism of Action

Codeine is a prodrug that requires metabolic transformation primarily by the hepatic enzyme Cytochrome P450 2D6 (CYP2D6) into its active form, morphine. This active metabolite subsequently functions as an agonist at mu-opioid receptors (mu-OR) throughout the central nervous system (CNS).

mu-OR binding initiates an inhibitory G-protein signaling cascade, leading to the hyperpolarization of neurons and a reduced release of excitatory neurotransmitters. This mechanistic action occurs in ascending afferent neural pathways (nociception) and medullary pathways controlling the involuntary cough reflex. This cellular activity regulates signal transmission within both systems.

Furthermore, the active metabolite engages peripheral mu-opioid receptors located within the enteric nervous system of the gastrointestinal (GI) tract. This binding contributes to reduced propulsive peristaltic contractions of the gut smooth muscle and increased sphincter tone, resulting in an altered intestinal transit time.

Dosage and Administration Information

How to Use Codeinefosfaat Teva

The administration of Codeinefosfaat Teva follows defined routes, dosing parameters, and duration limits. The medicine is predominantly used via the oral route, available in immediate-release tablets (commonly 15 mg and 30 mg strengths) and as an oral solution.

Official Dosing and Frequency

Administration follows a flexible, as-needed (PRN) schedule, guided by a minimum time interval between doses to prevent accumulation. Standard schedules define the dosing based on the use case:

Use Case	Standard Adult Dose Range	Frequency Constraint
Pain Relief	15 mg to 60 mg per dose	Every 4 to 6 hours
Antitussive (Cough)	15 mg to 30 mg per dose	Every 6 to 8 hours

The dosing is initiated at the lowest effective dose and is subject to a strict maximum daily dose, typically restricted to 240 mg.

Administration Requirements and Duration

Guidelines for intake specify certain conditions. Tablets must be swallowed whole with water and not be crushed, cut, or chewed, which is essential for preserving the intended release profile. The medicine may be taken with or without food. For acute pain, the treatment duration is limited to the shortest possible time, generally a maximum of 3 consecutive days. Furthermore, dosing requires adjustment for specific populations: the dose should be reduced or the interval prolonged for older adults and patients with renal or hepatic impairment to account for slower clearance.

Recent Clinical Evidence

Codeinefosfaat Teva: Recent Clinical Evidence

Evidence Investigating Use in Pain

Codeinefosfaat Teva was the subject of research investigating its use in pain. Studies reported findings regarding the change in pain intensity. Research examined the time to reported change in pain levels, and one trial explored whether combining Codeinefosfaat Teva with physical therapy impacted outcomes.

Studies in specific patient groups, such as those with severe liver conditions, were limited or excluded. Research into the drug's properties focused on its observed relationship with the pain threshold. Some studies assessed the parameters of use over an extended duration.

Research Exploring Activity in Related Conditions

Research has explored Codeinefosfaat Teva’s activity in relation to inflammation markers. One trial reported that the drug was associated with a change in C-reactive protein (CRP) levels. Researchers noted that further investigation is needed to evaluate its potential impact on disease progression, as clinical evidence for this activity remains limited.

Research investigated observed changes involving cytokine production. Further studies are looking at whether Codeinefosfaat Teva was comparable to other established treatments. The overall evidence base remains limited, and further research is ongoing to clarify the full scope of its studied effects.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Codeinefosfaat Teva (FAQ)

Q: Is constipation a guaranteed side effect of taking Codeinefosfaat Teva?

According to the official product information, constipation is listed as one of the most common adverse reactions. Regulatory guidance indicates that prolonged use is associated with a greater risk of adverse effects, including constipation.

Q: Can Codeinefosfaat Teva cause drowsiness or dizziness, and how long does this feeling typically last?

Drowsiness and dizziness are common side effects documented in the safety profile. Official information indicates that these effects on the central nervous system may last for a few days after discontinuing the medicine.

Q: What types of over-the-counter medicines might interact negatively with Codeinefosfaat Teva?

Official warnings state that this medicine may interact with certain over-the-counter products. This includes some antihistamines or cold remedies because combining them carries the risk of additive central nervous system (CNS) depression.

Q: What is the list of serious side effects that require immediate medical attention?

Regulatory warnings highlight that serious risks may require immediate medical attention. These documented risks include life-threatening respiratory depression (severely slowed or stopped breathing) and severe allergic reactions such as anaphylaxis.

Q: What is an 'ultra-rapid metabolizer' and how does it relate to the safety of Codeinefosfaat Teva?

An ultra-rapid metabolizer has naturally increased activity of the enzyme that converts codeine into morphine. Official information notes that this status is a contraindication (reason not to use the drug) due to the increased risk of dangerously high morphine levels and associated serious adverse events.

Q: Why does the effectiveness of codeine seem to vary so much between different people?

The effectiveness varies because codeine is a prodrug, meaning it only becomes active once the body converts it to morphine using the CYP2D6 enzyme. Individuals with reduced activity of this enzyme may have an altered response to the medicine.

Q: Does Codeinefosfaat Teva have any potential interaction with antidepressant medications?

Yes, regulatory documents note potential interactions. Concomitant use with serotonergic drugs (a class that includes some antidepressants) carries a documented risk of serotonin syndrome. It can also cause additive CNS depression when combined with other types of antidepressants.

Q: Is itching or skin rash a common reaction to codeine phosphate?

Itching and skin rashes are known adverse effects of codeine-containing medicines. However, official sources generally list these reactions as rare side effects.

Q: Is it true that taking codeine for a long time can sometimes make pain worse (opioid-induced hyperalgesia)?

Official instructions state that the drug should be used for the shortest possible time to minimize risks. This restriction is in place to reduce the potential for developing physical dependence and other long-term adverse effects, such as Adrenal Insufficiency.

Q: What are MAO inhibitors and why is there a 14-day rule about taking them with codeine?

MAOIs (Monoamine Oxidase Inhibitors) are a class of medication used to treat conditions like depression. Co-administration with MAOIs is strictly contraindicated due to the risk of enhanced respiratory depression. A mandatory 14-day period is required between stopping an MAOI and starting codeine.

Q: What is the 'phosphate' component in Codeinefosfaat Teva, and why is it included?

The drug’s active component is codeine phosphate. The phosphate is a salt form that is added to the active ingredient. It is included to make the medicine chemically stable and suitable for manufacturing into a tablet or oral solution.

Q: How quickly does Codeinefosfaat Teva usually start providing pain relief?

Official pharmacokinetic data indicates that the peak concentration of codeine in the bloodstream typically occurs about one hour after the medicine is taken orally. This is generally when the effects are noticeable.

Q: What is the expected duration of the effects from a single dose?

The half-life of codeine in the body is generally reported to be between 3 and 4 hours after oral administration. This half-life supports the typical 4- to 6-hour interval required between doses described in the official instructions.

Q: What does the 'Teva' part of the drug name refer to?

The 'Teva' part of the name refers to Teva Pharmaceutical Industries Ltd., which is the manufacturer of this specific generic medicine.

Q: Can Codeinefosfaat Teva be used for tension headaches or migraines?

Official documentation indicates that the medicine is indicated for the relief of mild to moderate pain, and is used for pain associated with headache.

Q: Is Codeinefosfaat Teva available without a prescription in some countries?

Regulatory status varies globally. In many major jurisdictions, including those whose regulatory bodies govern this drug (such as the US and Australia), medicines containing codeine generally require a prescription due to updated safety standards.

Q: What is the difference in action between Codeinefosfaat Teva and non-opioid pain relievers like paracetamol?

Codeine acts centrally by binding to opioid receptors after being converted to morphine. Non-opioid pain relievers, like paracetamol, generally act by inhibiting prostaglandin synthesis in the central nervous system, which is a different mechanism.

Q: Why do people sometimes report a feeling of well-being (euphoria) when taking codeine?

Euphoria is explicitly listed in regulatory documents as one of the known, though rare, central nervous system side effects of codeine.

Q: Is Codeinefosfaat Teva sometimes combined with other pain relief ingredients in a single tablet?

Yes, while Codeinefosfaat Teva itself is a single-ingredient product, codeine phosphate is commonly available in combination products with other analgesics. These combinations often include non-opioids like paracetamol (acetaminophen) or ibuprofen.

Q: What are the general signs of physical withdrawal from codeine that patients should be aware of?

Signs of physical withdrawal may occur if use is stopped suddenly after developing dependence. These signs can include restlessness, anxiety, muscle aches (myalgia), abdominal cramps, nausea, vomiting, or diarrhea.

Q: What does the term 'non-productive cough' mean in the context of this drug's use?

A non-productive cough is defined as a cough that does not produce phlegm or mucus (a dry cough). The medicine is indicated for its antitussive (cough suppressant) effect only for this type of dry cough.

Q: Can Codeinefosfaat Teva be used to treat symptoms of a cold or flu?

The medicine is indicated for the symptomatic relief of pain and for a non-productive cough. The medicine is indicated for its symptomatic effect and not for the treatment of the underlying cold or flu virus.

Q: Is it safe to take Codeinefosfaat Teva with certain herbal supplements?

Regulatory documents state that caution is advised regarding use with certain herbal supplements. For example, St. John's Wort is known to interact with the enzymes that metabolize codeine, potentially affecting its efficacy or safety.

Q: Is this medicine approved for use in other parts of the world, like the US or UK, under a different name?

Yes, medicines containing codeine phosphate are approved and used globally in various forms, including in the US, UK, Canada, and Australia. These are often sold under different brand or generic names.

How should Codeinefosfaat Teva be stored and disposed of?

How to Store and Dispose of Codeinefosfaat Teva

The storage and disposal of Codeinefosfaat Teva must follow strict regulatory guidelines to maintain product stability and ensure public safety.

Official Storage Requirements

Codeinefosfaat Teva tablets must be stored at a temperature not exceeding 25 C and in the original container. The product is generally considered stable when exposed to light, but the container should be kept tightly closed where applicable. Due to the high risk associated with accidental ingestion, the medication must always be kept out of the sight and reach of children.

Disposal Instructions

Unused or expired Codeinefosfaat Teva must be disposed of in accordance with local regulations for pharmaceutical waste. The preferred method for this opioid medication is often through an authorized drug take-back program. The tablets should generally not be flushed down the toilet or sink.

Regulatory Concern	Description
Opioid Risk	High potential for addiction, abuse, and misuse, which can lead to overdose and death.
Respiratory Depression	Risk of life-threatening slowed or stopped breathing, particularly upon initiating treatment or increasing the dose.
Metabolism Risk	Contraindicated in children younger than 12 and in CYP2D6 ultra-rapid metabolizers of any age due to rapid conversion to toxic levels of morphine.
Allergic Reactions	Potential for severe allergic reactions (anaphylaxis), requiring immediate medical attention.

Property	Documented Overdose Signs and Actions
Documented Manifestations	Symptoms of overdose include marked Central Nervous System (CNS) depression, such as severe somnolence and confusion, progressing to stupor and coma. Respiratory depression (slow, shallow breathing) and pinpoint pupils (miosis) are recognized clinical signs. Other presentations include hypotension and cold, clammy skin [NIH MedlinePlus Codeine Overdose].
Severe Outcomes	The most serious documented outcomes are apnea (stopped breathing), circulatory collapse, and death [FDA Codeine Prescribing Information]. Brain damage is a risk if respiratory compromise is prolonged.
Emergency Actions	Immediate medical attention must be sought or emergency services called immediately for any known or suspected overdose, or if symptoms such as slow breathing or unresponsiveness manifest [EMA Codeine Phosphate SmPC]. The official treatment strategy is symptomatic and supportive, and includes the administration of the specific opioid antagonist, Naloxone, to reverse respiratory and CNS depression [NIH MedlinePlus Codeine Overdose].

Codeinefosfaat Teva